logo

For the Inventor, By the Inventor

Tokyo, Japan

Mochida Pharmaceutical Co., Ltd.

Calculating rank
USPTO Granted Patents = 229

% Expired Patents = 15.7



Trademarks = 5

Forward Citations = 3,028

Loading Chart...
Loading Chart...

312 inventors (with patents filed for the assignee):

goldMedal Ei Mochida (41 out of 52 patents)

silverMedal Kamon Shirakawa (24 out of 24 patents)

bronzeMedal Shoji Furusako (16 out of 19 patents)

4.  Tsutomu Satoh (15 out of 38 patents)

5.  Haruo Ohnishi (15 out of 18 patents)

6.  Masahiro Nobuhara (14 out of 14 patents)

7.  Kazuo Kato (14 out of 79 patents)

8.  Hirosato Fujii (13 out of 13 patents)

9.  Yasuo Suzuki (13 out of 27 patents)

10.  Toshinori Kanamori (12 out of 12 patents)

11.  Motoo Yamagata (11 out of 11 patents)

12.  Hiroshi Kosuzume (11 out of 14 patents)

13.  Hideki Origasa (10 out of 11 patents)

14.  Yuji Matsuzawa (10 out of 21 patents)

15.  Yasushi Saito (10 out of 37 patents)


Core Competencies:
Heterocyclidene Acetamide
Alginate Gel
Intervertebral Disc
Eicosapentaenoic Acid
Anti-Presepsin Antibody
Nerve Regeneration
Cardiovascular Prevention
Non-Alcoholic Steatohepatitis
Pyrazole Derivative
Cyclic Amide
Jelly Composition
Freeze-Dried Alginate

229 patents:

1. 12527740 - Suspension containing heterocyclidene acetamide derivative (2026-01-20),
2. 12502375 - Pharmaceutical drug containing heterocyclidene acetamide derivative (2025-12-23),
3. 12491208 - Combination and method for treating subject using alginate (2025-12-09),
4. 12479933 - Crosslinked alginic acid structure (2025-11-25),
5. 12478637 - Method for suppressing intervertebral disc pain (2025-11-25),
6. 12478636 - Composition for treating intervertebral disc (2025-11-25),
7. 12349886 - Retractor (2025-07-08),
8. 12312574 - Polymer-coated crosslinked alginate gel fiber (2025-05-27),
9. 12286414 - Method for producing heterocyclidene acetamide derivative (2025-04-29),
10. 12226544 - Brain damage recovery material (2025-02-18),
11. 12151025 - Freeze-dried alginic acid preparation (2024-11-26),
12. 12134607 - Crystals of tetrahydronaphthyl urea derivative (2024-11-05),
13. 11969437 - Alginate liquid preparation (2024-04-30),
14. 11932708 - Crosslinked alginic acid (2024-03-19),
15. 11911480 - Self-emulsifying composition of ω-3 fatty acid (2024-02-27),
Company Overview
Mochida Pharmaceutical Co., Ltd. is a Tokyo-based company specializing in the development and manufacturing of pharmaceutical compositions. The organization focuses on innovative therapeutic solutions, particularly in areas such as nerve regeneration, cardiovascular prevention, and treatment for non-alcoholic steatohepatitis. Its research encompasses advanced technologies including heterocyclidene acetamide and alginate gel, contributing to significant advancements in medical science and patient care.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

229 Patents

#319 in Tokyo

#642 in Japan

#3,747 in the World

Tokyo, JP
Tokyo, Japan

Mochida Pharmaceutical Co., Ltd.

Forward Citations = 3,028

312 inventors:

goldMedal Ei Mochida (41 out of 52 patents)

silverMedal Kamon Shirakawa (24 out of 24 patents)

bronzeMedal Shoji Furusako (16 out of 19 patents)

4.  Tsutomu Satoh (15 out of 38 patents)

5.  Haruo Ohnishi (15 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mochida Pharmaceutical Co., Ltd.. Retrieved from https://idiyas.com/company/mochida-pharmaceutical-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…